METHODS	In a randomized , double-blind placebo-controlled multicenter trial ( Deutsche Kardiale Autonome Neuropathie [ DEKAN ] Study ) , NIDDM patients with reduced HRV were randomly assigned to treatment with daily oral dose of 800 mg ALA ( n = 39 ) or placebo ( n = 34 ) for 4 months .\